# Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

> **NCT02346084** · PHASE1 · COMPLETED · sponsor: **International Partnership for Microbicides, Inc.** · enrollment: 19 (actual)

## Conditions studied

- HIV/AIDS

## Interventions

- **DRUG:** Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)

## Key facts

- **NCT ID:** NCT02346084
- **Lead sponsor:** International Partnership for Microbicides, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-09-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346084, "Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02346084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*